Verve Therapeutics (VERV)

Company Profile

Verve Therapeutics is a biotechnology company created with a singular focus: to protect the world from heart disease. Founded by world-leading experts in cardiovascular medicine, human genetics and gene editing, the company aims to develop transformative, once-and-done therapies for coronary heart disease. Verve’s gene editing medicines are designed to safely edit the genome of adults and mimic naturally occurring gene variants to permanently lower LDL cholesterol and triglyceride levels. The company is advancing a pipeline of precision genetic medicines, led by VERVE-101, which is being developed initially for heterozygous familial hypercholesterolemia, a potentially fatal genetic heart disease.

Company profile

Ticker

VERV

Exchange

Website

Incorporated

Location

Fiscal year end

Sector

Manufacturing > Pharmaceutical Preparation Manufacturing

Industry (SIC)

Pharmaceutical Preparations

Pfizer • Johnson & Johnson • Merck & Co • Abbott Laboratories • Teva- Pharmaceutical Industries • Bristol-Myers Squibb • Lilly(Eli) & Co • Viatris • Abbvie • Bausch Health Companies ...

SEC CIK

0001840574

Corporate docs

Articles of Incorporation & Bylaws

Underwriting Agreements

Indentures

Material Contracts & Credit Agreements

Subsidiaries Lists

IRS number

824800132

VERV stock data

1M 1Y 5Y

Analyst ratings and price targets

Last 3 months

Latest filings (excl ownership)

View all

S-8

Registration of securities for employees

2 Mar 23

Verve Therapeutics Provides Pipeline Progress and Reports Fourth Quarter and Full Year 2022 Financial Results

2 Mar 23

8-K

Amendments to Articles of Incorporation or Bylaws

7 Nov 22

Verve Therapeutics Provides Regulatory Update on VERVE-101 Investigational New Drug Application and Reports Third Quarter 2022 Financial Results

7 Nov 22

S-3ASR

Automatic shelf registration

9 Aug 22

Verve Therapeutics Provides Corporate Updates and Reports Second Quarter 2022 Financial Results

9 Aug 22

Latest ownership filings

View all

ARCH Venture Fund X, L.P.

Financial summary

Financial statements Chart VERV financial data

Quarter (USD)	Dec 22	Sep 22	Jun 22	Mar 22
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Annual (USD)	Dec 22	Dec 21
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Cash burn rate (est.)	Burn method: Change in cash		Burn method: Operating income		Burn method: FCF (opex + capex)
	Last Q	Avg 4Q	Last Q	Avg 4Q	Last Q	Avg 4Q
Cash on hand (at last report)	120.24 mm	120.24 mm	120.24 mm	120.24 mm	120.24 mm	120.24 mm
Cash burn (monthly)	53.87 mm	(no burn)	15.90 mm	13.81 mm	(no burn)	2.61 mm
Cash used (since last report)	144.11 mm	n/a	42.54 mm	36.94 mm	n/a	6.97 mm
Cash remaining	-23.87 mm	n/a	77.69 mm	83.30 mm	n/a	113.27 mm
Runway (months of cash)	-0.4	n/a	4.9	6.0	n/a	43.5

Beta Read what these cash burn values mean

Financial data from company earnings reports.

Institutional ownership, Q4 2022

VERV institutional ownership history Ownership history

13F holders	Current	Prev Q	Change
Total holders	124	128	-3.1%
Opened positions	28	47	-40.4%
Closed positions	32	21	+52.4%
Increased positions	46	54	-14.8%
Reduced positions	30	16	+87.5%

13F shares	Current	Prev Q	Change
Total value	1.14 tn	2.15 bn	+53125.9%
Total shares	77.55 mm	73.24 mm	+5.9%
Total puts	56.40 k	122.00 k	-53.8%
Total calls	435.00 k	411.70 k	+5.7%
Total put/call ratio	0.1	0.3	-56.2%

Largest owners	Shares	Value	Change
GOOG Alphabet	10.55 mm	$204.12 bn	-3.9%
GV 2017	10.55 mm	$0.00	-3.9%
FMR	6.91 mm	$133.62 bn	-7.7%
STT State Street	4.47 mm	$86.51 bn	NEW
ARK Investment Management	4.37 mm	$84.48 bn	+28.6%
Vanguard	3.81 mm	$73.76 bn	+4.2%
BLK Blackrock	3.59 mm	$69.55 bn	+6.5%
ARCH Venture Fund X	2.51 mm	$92.50 mm	0.0%
Casdin Capital	2.29 mm	$44.32 bn	-27.9%
FHI Federated Hermes	2.08 mm	$40.21 bn	+18.8%

Largest transactions	Shares	Bought/sold	Change
STT State Street	4.47 mm	+4.47 mm	NEW
ARK Investment Management	4.37 mm	+971.97 k	+28.6%
Partner Fund Management	217.30 k	-951.51 k	-81.4%
Casdin Capital	2.29 mm	-887.60 k	-27.9%
Deep Track Capital	0.00	-775.00 k	EXIT
Deerfield Management	0.00	-750.00 k	EXIT
FMR	6.91 mm	-576.93 k	-7.7%
T. Rowe Price Investment Management	1.80 mm	+544.83 k	+43.4%
Avidity Partners Management	1.57 mm	+522.29 k	+50.1%
CMTDF Sumitomo Mitsui Trust	1.23 mm	+452.75 k	+58.4%

Data from 13F filings, for the last complete 13F reporting period. For most recent data, click the ownership history button. Values as filed, not updated for current price. Long positions only.

Recent insider trades

VERV insider ownership history Insider history

Date	Owner	Security	Transaction	Code	Indirect	10b5-1	$Price	#Shares	$Value	#Remaining
14 Feb 23	MacLean Michael F	Stock Option Common Stock	Grant	Acquire A	No	No	21.76	7,000	152.32 k	7,000
14 Feb 23	Andrew Bellinger	Stock Option Common Stock	Grant	Acquire A	No	No	21.76	182,800	3.98 mm	182,800
14 Feb 23	Allison Dorval	Stock Option Common Stock	Grant	Acquire A	No	No	21.76	182,800	3.98 mm	182,800
14 Feb 23	Sekar Kathiresan	Stock Option Common Stock	Grant	Acquire A	No	No	21.76	550,200	11.97 mm	550,200